Chinese General Practice ›› 2022, Vol. 25 ›› Issue (24): 3013-3017.DOI: 10.12114/j.issn.1007-9572.2022.0238
• Article • Previous Articles Next Articles
Received:
2022-02-15
Revised:
2022-04-08
Published:
2022-08-20
Online:
2022-06-02
Contact:
Ke QIN
About author:
通讯作者:
秦克
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0238
观察时间 | FVC(L) | FEV1(L) | PEF(L/s) | CAT评分(分) | 血清miR-210表达水平 | 血清miR-181a表达水平 |
---|---|---|---|---|---|---|
治疗前 | 2.49±0.76 | 1.38±0.44 | 3.61±0.93 | 16.33±4.10 | 22.01±6.17 | 1.38±0.47 |
治疗后 | 2.78±0.81 | 1.60±0.51 | 4.32±1.03 | 11.57±3.27 | 17.41±5.29 | 1.09±0.32 |
t值 | 2.421 | 3.029 | 4.745 | 8.417 | 5.249 | 4.730 |
P值 | 0.017 | 0.003 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 1 Comparison of pulmonary function parameters,CAT score,and serum miR-210 and miR-181a levels before and after four-week budesonide and formoterol inhalation treatment in COPD patients
观察时间 | FVC(L) | FEV1(L) | PEF(L/s) | CAT评分(分) | 血清miR-210表达水平 | 血清miR-181a表达水平 |
---|---|---|---|---|---|---|
治疗前 | 2.49±0.76 | 1.38±0.44 | 3.61±0.93 | 16.33±4.10 | 22.01±6.17 | 1.38±0.47 |
治疗后 | 2.78±0.81 | 1.60±0.51 | 4.32±1.03 | 11.57±3.27 | 17.41±5.29 | 1.09±0.32 |
t值 | 2.421 | 3.029 | 4.745 | 8.417 | 5.249 | 4.730 |
P值 | 0.017 | 0.003 | <0.001 | <0.001 | <0.001 | <0.001 |
观察指标 | 治疗前血清miR-210表达水平 | 治疗前血清miR-181a表达水平 | ||
---|---|---|---|---|
r值 | P值 | r值 | P值 | |
治疗前FVC | -0.209 | 0.055 | -0.193 | 0.075 |
治疗前FEV1 | -0.177 | 0.103 | -0.181 | 0.095 |
治疗前PEF | -0.169 | 0.120 | -0.172 | 0.113 |
治疗前CAT评分 | 0.584 | <0.001 | 0.604 | <0.001 |
Table 2 Correlations of serum miR-210 and miR-181a levels with lung function parameters and CAT score in COPD patients before four-week budesonide and formoterol inhalation
观察指标 | 治疗前血清miR-210表达水平 | 治疗前血清miR-181a表达水平 | ||
---|---|---|---|---|
r值 | P值 | r值 | P值 | |
治疗前FVC | -0.209 | 0.055 | -0.193 | 0.075 |
治疗前FEV1 | -0.177 | 0.103 | -0.181 | 0.095 |
治疗前PEF | -0.169 | 0.120 | -0.172 | 0.113 |
治疗前CAT评分 | 0.584 | <0.001 | 0.604 | <0.001 |
观察指标 | 治疗后血清miR-210表达水平 | 治疗后血清miR-181a表达水平 | ||
---|---|---|---|---|
r值 | P值 | r值 | P值 | |
治疗后FVC | -0.211 | 0.051 | -0.206 | 0.057 |
治疗后FEV1 | -0.633 | <0.001 | -0.635 | <0.001 |
治疗后PEF | -0.161 | 0.139 | -0.158 | 0.146 |
治疗后CAT评分 | 0.198 | 0.068 | 0.174 | 0.109 |
Table 3 Correlation analysis of serum miR-210 and miR-181a levels with lung function parameters and CAT score after four-week budesonide and formoterol inhalation treatment
观察指标 | 治疗后血清miR-210表达水平 | 治疗后血清miR-181a表达水平 | ||
---|---|---|---|---|
r值 | P值 | r值 | P值 | |
治疗后FVC | -0.211 | 0.051 | -0.206 | 0.057 |
治疗后FEV1 | -0.633 | <0.001 | -0.635 | <0.001 |
治疗后PEF | -0.161 | 0.139 | -0.158 | 0.146 |
治疗后CAT评分 | 0.198 | 0.068 | 0.174 | 0.109 |
组别 | 例数 | 年龄( | 男性〔n(%)〕 | BMI( | 病程( | 戒烟时间( | 血清miR-210表达水平( | 血清miR-181a表达水平( | ||
---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | 治疗前 | 治疗后 | |||||||
有效组 | 39 | 59.7±6.9 | 25(64.10) | 22.4±1.6 | 12.89±4.52 | 6.0±1.4 | 18.29±2.21 | 13.96±2.93 | 1.03±0.17 | 0.69±0.13 |
无效组 | 47 | 61.5±7.6 | 33(70.21) | 22.2±1.8 | 14.05±4.34 | 5.5±1.1 | 25.73±4.09 | 20.86±3.22 | 1.73±0.26 | 1.49±0.25 |
t(χ2)值 | 1.172 | 0.361a | 0.611 | 1.211 | 1.595 | 10.733 | 10.396 | 17.002 | 19.065 | |
P值 | 0.245 | 0.547 | 0.543 | 0.229 | 0.114 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 4 The clinical data in COPD patients with and without responses to four-week budesonide and formoterol inhalation treatment
组别 | 例数 | 年龄( | 男性〔n(%)〕 | BMI( | 病程( | 戒烟时间( | 血清miR-210表达水平( | 血清miR-181a表达水平( | ||
---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | 治疗前 | 治疗后 | |||||||
有效组 | 39 | 59.7±6.9 | 25(64.10) | 22.4±1.6 | 12.89±4.52 | 6.0±1.4 | 18.29±2.21 | 13.96±2.93 | 1.03±0.17 | 0.69±0.13 |
无效组 | 47 | 61.5±7.6 | 33(70.21) | 22.2±1.8 | 14.05±4.34 | 5.5±1.1 | 25.73±4.09 | 20.86±3.22 | 1.73±0.26 | 1.49±0.25 |
t(χ2)值 | 1.172 | 0.361a | 0.611 | 1.211 | 1.595 | 10.733 | 10.396 | 17.002 | 19.065 | |
P值 | 0.245 | 0.547 | 0.543 | 0.229 | 0.114 | <0.001 | <0.001 | <0.001 | <0.001 |
Figure 1 ROC curve of pre-treatment serum miR-210 and miR-181a levels in predicting the treatment effect of four-week budesonide and formoterol inhalation in COPD patients
指标 | AUC(95%CI) | P值 | 临界值 | 灵敏度 | 特异度 |
---|---|---|---|---|---|
miR-210 | 0.807(0.538,0.929) | 0.032 | 19.65 | 0.733 | 0.767 |
miR-181a | 0.844(0.552,0.960) | 0.011 | 1.29 | 0.779 | 0.802 |
Table 5 Performance of pre-treatment serum miR-210 and miR-181a levels in predicting the treatment effect of four-week budesonide and formoterol inhalation in stable COPD patients
指标 | AUC(95%CI) | P值 | 临界值 | 灵敏度 | 特异度 |
---|---|---|---|---|---|
miR-210 | 0.807(0.538,0.929) | 0.032 | 19.65 | 0.733 | 0.767 |
miR-181a | 0.844(0.552,0.960) | 0.011 | 1.29 | 0.779 | 0.802 |
[1] |
|
[2] |
|
[3] |
郑研,王晖,李岚,等. miR-181a诱导慢性淋巴细胞白血病细胞周期阻滞及细胞凋亡的分子机制探讨[J]. 现代肿瘤医学,2020,28(18):3118-3122. DOI:10.3969/j.issn.1672-4992.2020.18.005.
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志,2013,36(4):255-264. DOI:10.3760/cma.j.issn.1001-0939.2013.04.007.
|
[9] |
|
[10] |
李冰,杨元立,王美霞,等. 巨噬细胞移动抑制因子在慢性阻塞性肺疾病患者肺组织中的表达及意义[J]. 中华急诊医学杂志,2019,28(9):1123-1127. DOI:10.3760/cma.j.issn.1671-0282.2019.09.012.
|
[11] |
|
[12] |
|
[13] |
李渊,姜启栋,梅松涛,等. miR-181a靶向SIRT1对脓毒症诱导的小鼠急性肺损伤的影响及作用机制[J]. 西安交通大学学报:医学版,2020,41(4):516-524. DOI:10.7652/jdyxb202004010.
|
[14] |
|
[15] |
邢江,杨亚萍. COPD患者血清microRNA-210、HIF-1α水平与心率变异性及肺功能的相关性[J]. 中国现代医学杂志,2020,30(10):96-101. DOI:10.3969/j.issn.1005-8982.2020.10.020.
|
[16] |
李翠娟,唐颖,慕丽娜,等. 稳定期COPD患者血清miR-181a与炎性因子的关系及对急性加重和死亡的预测价值[J]. 临床急诊杂志,2020,21(7):567-571. DOI:10.13201/j.issn.1009-5918.2020.07.011.
|
[17] |
李井华,张慧君,王红艳,等. miR-210、miR-155和miR-34a在SLE患者外周血中的表达水平及其与病情严重程度的相关性分析[J]. 中国中西医结合肾病杂志,2020,21(4):5-7.
|
[18] |
|
[19] |
|
[20] |
刘灿,龚海东,王伟灿,等. miR-210/VMP1信号传导通路在脑胶质瘤中作用的研究进展[J]. 现代肿瘤医学,2020,28(2):342-345. DOI:10.3969/j.issn.1672-4992.2020.02.038.
|
[21] |
粱珍珍,吕燕平,张艳莉,等. miR-181a参与调控香烟提取物诱导的NR8383肺泡巨噬细胞自噬紊乱与促炎因子的生成[J]. 中国病理生理杂志,2019,35(4):710-717. DOI:10.3969/j.issn.1000-4718.2019.04.021.
|
[22] |
|
[1] | YAO Yuzhong, MA Xiaojun, SONG Huan, ZHONG Yu. The Management Effect of Diabetes "1358 model" on Community Diabetes Patients Based on "Precision Management Combining General Care and Specialty Care" [J]. Chinese General Practice, 2023, 26(34): 4308-4314. |
[2] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[3] | WANG Qiushi, LI Hongwei. The Predictive Value of CHA2DS2-VASc Score on Major Adverse Cardiovascular Events in Patients with Three Vessels or Left Main Diseases of Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(33): 4130-4136. |
[4] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[5] | MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102. |
[6] | LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei. Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia [J]. Chinese General Practice, 2023, 26(32): 4007-4012. |
[7] | YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779. |
[8] | YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790. |
[9] | SHI Xiaoqi, LUO Nandu, HUANG Jiaojiao, DU Zuochen, HUANG Pei, CAO Xiuli, CHEN Yan, HE Zhixu. Correlation between Aspartate Aminotransferase/Alanine Aminotransferase and Prognosis of Hemophagocytic Lymphohistiocytosis in Children [J]. Chinese General Practice, 2023, 26(30): 3801-3808. |
[10] | LU Bin, XIANG Chong, YUAN Xuesong, CAI Gaojun, WEI Wenfeng, YAN Yongmin. Effectiveness, Safety and Satisfaction of Distal Transradial Artery Approach in Cerebral Angiography [J]. Chinese General Practice, 2023, 26(27): 3378-3382. |
[11] | TANG Shilan, XIE Kexin, LIU Lingyu, QI Tiantian, YANG Yansui. Advances in Rehabilitation Outcomes and Care in Patients with Prolonged Disorders of Consciousness [J]. Chinese General Practice, 2023, 26(27): 3342-3348. |
[12] | YAO Junjie, SHANG Qiangqiang, WANG Yufeng, LI Jiahui, LIU Chang, PANG Tingting. Wearable Inertial Sensors-based Efficacy Evaluation of Comprehensive Traditional Chinese Medicine Therapy for Lumbar Disc Herniation Due to Qi-stagnation and Blood-stasis [J]. Chinese General Practice, 2023, 26(27): 3450-3455. |
[13] | LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372. |
[14] | ZHANG Yanjing, SONG Xiaokun. Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors [J]. Chinese General Practice, 2023, 26(23): 2930-2935. |
[15] | SUN Shuaigang, SHENG Xiaoxiao, ZHANG Wenhui, TIAN Huijuan, ZHAI Yaling. The Analysis of Clinicopathological Characters and Short-term Prognosis in Idiopathic Membranous Nephropathy Patients with Immunoglobulin G4 Combined with Other Different Immunoglobulin G Subtypes Deposition [J]. Chinese General Practice, 2023, 26(21): 2632-2638. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||